Copyright
©The Author(s) 2016.
World J Gastroenterol. Feb 14, 2016; 22(6): 2133-2141
Published online Feb 14, 2016. doi: 10.3748/wjg.v22.i6.2133
Published online Feb 14, 2016. doi: 10.3748/wjg.v22.i6.2133
Characteristics | Total (n = 528) | NODM group (n = 131) | Non-NODM group (n = 397) | P value |
Recipient characteristics | ||||
Age (yr) | 44.93 ± 9.41 | 46.24 ± 9.54 | 44.50 ± 9.34 | 0.068 |
Gender (male) | 446 (84.5) | 144 (87.0) | 332 (83.6) | 0.352 |
Child-Pugh (A/B/C) | 136/223/169 | 39/44/48 | 97/179/121 | 0.069 |
MELD Score | 13 (6-40) | 15 (6-40) | 13 (6-40) | 0.010 |
BMI ≥ 25 pre-LT | 110 (20.8) | 36 (27.5) | 74 (18.6) | 0.006 |
Hypertension pre-LT | 12 (2.3) | 7 (5.3) | 5 (1.3) | 0.017 |
Dyslipidemia pre-LT | 41 (8.2) | 15 (11.5) | 26 (6.5) | 0.069 |
Indications for LT | ||||
Hepatitis B virus disease | 420 (79.5) | 102 (77.9) | 318 (80.1) | 0.582 |
Hepatitis C virus disease | 6 (1.1) | 1 (0.8) | 5 (1.3) | > 0.990 |
Alcoholic cirrhosis | 16 (3.0) | 7 (5.3) | 9 (2.3) | 0.137 |
Tumors | 269 (50.9) | 56 (42.7) | 213 (53.7) | 0.030 |
Mean cTAC (ng/mL) | 5.26 ± 2.91 | 7.66 ± 3.41 | 4.47 ± 2.22 | < 0.001 |
Rapamycin administration | 129 (24.4) | 30 (22.9) | 99 (24.9) | 0.638 |
MMF administration | 322 (61.0) | 78 (59.5) | 244 (61.5) | 0.696 |
Complications post-LT | ||||
BMI ≥ 25 post-LT | 128 (24.2) | 40 (30.5) | 88 (22.2) | 0.053 |
Hypertension post-LT | 67 (12.7) | 22 (16.8) | 45 (11.3) | 0.104 |
Dyslipidaemia post-LT | 175 (33.1) | 63 (48.1) | 112 (28.2) | < 0.001 |
Cardio-cerebral events post-LT | 18 (3.4) | 10 (7.6) | 8 (2.0) | 0.005 |
CKD post-LT | 91 (17.2) | 28 (21.4) | 63 (15.9) | 0.148 |
AR post-LT | 58 (11.0) | 20 (15.3) | 38 (9.6) | 0.071 |
CR post-LT | 20 (3.8) | 9 (6.9) | 11 (2.8) | 0.062 |
Infection post-LT | 165 (28.7) | 65 (36.7) | 100 (25.2) | 0.042 |
Graft failure | 52 (9.8) | 20 (15.3) | 32 ( 8.1) | 0.016 |
Donor characteristics | ||||
Age (yr) | 34.01 ± 8.75 | 33.62 ± 8.33 | 34.13 ± 8.89 | 0.559 |
Gender (male) | 443 (84.5) | 108 (82.4) | 335 (84.4) | 0.600 |
Donor type (LDLT) | 158 (29.9) | 34 (26.0) | 124 (31.2) | 0.252 |
- Citation: Song JL, Gao W, Zhong Y, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Wu H, Xu MQ, Chen ZY, Wei YG, Jiang L, Yang J. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation. World J Gastroenterol 2016; 22(6): 2133-2141
- URL: https://www.wjgnet.com/1007-9327/full/v22/i6/2133.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i6.2133